Evidence map›Paper›PMID 26199136›Full record

ArticleHepatology (Baltimore, Md.)2015

Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium.

Roberto Scirpo, Romina Fiorotto, Ambra Villani, Mariangela Amenduni, Carlo Spirli, Mario Strazzabosco

Abstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 146 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Roberto ScirpoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Romina FiorottoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Ambra VillaniSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Mariangela AmenduniSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Carlo SpirliSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Mario StrazzaboscoSection of Digestive Diseases, Liver Center, Yale University, New Haven, CT.
Yale University · USUniversity of Milano-Bicocca · IT

Funding

Yale Liver CenterP30DK034989 · NIDDK · YALE UNIVERSITY · PI YASUKO IWAKIRI · 1986 to 2026
$31.1M
Yale Mouse Metabolic Phenotyping CenterU24DK059635 · NIDDK · YALE UNIVERSITY · PI SHULMAN, GERALD I · 2001 to 2015
$8.9M
Liver disease in CF: CFTR controls innate immunity in biliary epitheliumR01DK096096 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2013 to 2022
$4.6M
Epithelial Angiogenic Signaling in Polycystic Diseases of the LiverR01DK079005 · NIDDK · YALE UNIVERSITY · PI STRAZZABOSCO, MARIO · 2008 to 2017
$3.5M
NIDDK NIH HHS DK34989NIDDK NIH HHS P30 DK034989NIDDK NIH HHS R01 DK079005NIDDK NIH HHS R01 DK096096NIDDK NIH HHS U24 DK-059635NIDDK NIH HHS U24 DK059635Telethon GGP12133
6 · The paper itself

Abstract

unlabelledCystic fibrosis-associated liver disease is a chronic cholangiopathy that negatively affects the quality of life of cystic fibrosis patients. In addition to reducing biliary chloride and bicarbonate secretion, up-regulation of toll-like receptor 4/nuclear factor kappa light-chain-enhancer of activated B cells (NF-κB)-dependent immune mechanisms plays a major role in the pathogenesis of cystic fibrosis-associated liver disease and may represent a therapeutic target. Nuclear receptors are transcription factors that regulate several intracellular functions. Some nuclear receptors, including peroxisome proliferator-activated receptor-γ (PPAR-γ), may counterregulate inflammation in a tissue-specific manner. In this study, we explored the anti-inflammatory effect of PPAR-γ stimulation in vivo in cystic fibrosis transmembrane conductance regulator (Cftr) knockout mice exposed to dextran sodium sulfate and in vitro in primary cholangiocytes isolated from wild-type and from Cftr-knockout mice exposed to lipopolysaccharide. We found that in CFTR-defective biliary epithelium expression of PPAR-γ is increased but that this does not result in increased receptor activity because the availability of bioactive ligands is reduced. Exogenous administration of synthetic agonists of PPAR-γ (pioglitazone and rosiglitazone) up-regulates PPAR-γ-dependent genes, while inhibiting the activation of NF-κB and the secretion of proinflammatory cytokines (lipopolysaccharide-induced CXC chemokine, monocyte chemotactic protein-1, macrophage inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chemoattractant) in response to lipopolysaccharide. PPAR-γ agonists modulate NF-κB-dependent inflammation by up-regulating nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor alpha, a negative regulator of NF-κB. Stimulation of PPAR-γ in vivo (rosiglitazone) significantly attenuates biliary damage and inflammation in Cftr-knockout mice exposed to a dextran sodium sulfate-induced portal endotoxemia.

conclusionThese studies unravel a novel function of PPAR-γ in controlling biliary epithelium inflammation and suggest that impaired activation of PPAR-γ contributes to the chronic inflammatory state of CFTR-defective cholangiocytes.

Indexed as

AnimalsCells, CulturedCholangitisCystic FibrosisCytokinesEpitheliumI-kappa B ProteinsLipopolysaccharidesMiceMice, Inbred C57BLMice, Inbred CFTRNF-kappa BNF-KappaB Inhibitor alphaPPAR gammaCytokinesI-kappa B ProteinsLipopolysaccharidesNF-kappa BNF-KappaB Inhibitor alphaNfkbia protein, mousePPAR gamma

Identifiers

PMID26199136
PMCPMC4618241
OpenAlexW2135566179

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.